Drugs / APP-derived islets
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07118475 | Oct 2025 → May 2027 expected | type 2 diabetes mellitus | Shanghai Zhongshan Hospital | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APP-derived islets | “Following autologous transplantation of APP-derived islets, the transplanted islets are expected to survive at the implantation site, stably secrete insulin, and thereby reduce...” NCT07118475 ↗ |
| Action | Restore | “stably secrete insulin, and thereby reduce or potentially eliminate the need for exogenous insulin” NCT07118475 ↗ |
| Modality | Cell therapy | “these cells will be transplanted via injection beneath the anterior rectus sheath” NCT07118475 ↗ |
| Route | Other | “injection beneath the anterior rectus sheath” NCT07118475 ↗ |